ALB and hypothyroidism: Percentages of patients manifesting CTCAE grade 3 adverse events were 7% for thrombocytopenia and elevated aspartate aminotransferase, 5% for ascites, 4% for hepatic encephalopathy and increase of serum bilirubin and creatinine, 3% for appetite loss, decrease of serum albumin and proteinuria and 1% for general fatigue and hypothyroidism.